Online first
Clinical vignette
Published online: 2024-12-04
Acute promyelocytic leukemia in patient with chronic myeloid leukemia treated with tyrosine kinase inhibitors
1
, 2, 2, 2, 1
, 2, 2, 2, 1
DOI: 10.5603/ahp.102542
Abstract
Not available
Keywords: acute promyelocytic leukemiachronic myeloid leukemiatyrosine kinase inhibitorall-trans retinoic acidarsenic trioxidegranulocyte alkaline phosphatase
References
- Capelli D, Menotti D, Fiorentini A, et al. Secondary Acute Myeloid Leukemia: Pathogenesis and Treatment. Leukemia. 2022: 111–127.
- Szotkowski T, Rohon P, Zapletalova L, et al. Secondary acute myeloid leukemia - a single center experience. Neoplasma. 2010; 57(2): 170–178.
- Berger R, Bernheim A, Daniel MT, et al. t(15;17) in a promyelocytic form of chronic myeloid leukemia blastic crisis. Cancer Genet Cytogenet. 1983; 8(2): 149–152.
- Kumar V, Garg M, Chaudhary N, et al. An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States. PeerJ. 2018; 6: e4342.
- Parsi M, Budak-Alpdogan T. Promyelocytic Blast Crisis of Chronic Myeloid Leukemia in a Patient Undergoing Therapy with a Tyrosine Kinase Inhibitor. Cureus. 2020; 12(3): e7217.
- Abbasi AM, Shaikh U. Chronic myeloid leukemia developing in treated acute promyelocytic leukemia. Hematol Transfus Cell Ther. 2022; 44(4): 602–605.
- Duffield AS, Aoki J, Levis M, et al. Clinical and pathologic features of secondary acute promyelocytic leukemia. Am J Clin Pathol. 2012; 137(3): 395–402.
- Neves H, Ramos C, da Si, et al. The nuclear topography of ABL, BCR, PML, and RARalpha genes. Blood. ; 1999: PMID.
